Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in MRD Positive B-precursor ALL (BLAST)
NCT00560794Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2008
- Primary completion
- Sep 2009
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Started Jan 2008; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00560794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560794.